Renaissance Technologies LLC Cuts Stock Position in iCAD, Inc. (NASDAQ:ICAD)

Renaissance Technologies LLC trimmed its stake in iCAD, Inc. (NASDAQ:ICAD - Free Report) by 20.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 475,593 shares of the technology company's stock after selling 125,697 shares during the quarter. Renaissance Technologies LLC owned 1.79% of iCAD worth $870,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also modified their holdings of the company. Perritt Capital Management Inc boosted its position in shares of iCAD by 1.9% during the 4th quarter. Perritt Capital Management Inc now owns 189,100 shares of the technology company's stock valued at $346,000 after acquiring an additional 3,600 shares in the last quarter. waypoint wealth counsel grew its stake in iCAD by 44.0% in the fourth quarter. waypoint wealth counsel now owns 14,400 shares of the technology company's stock valued at $26,000 after acquiring an additional 4,400 shares during the period. Wells Fargo & Company MN boosted its position in shares of iCAD by 51.3% during the fourth quarter. Wells Fargo & Company MN now owns 39,542 shares of the technology company's stock worth $72,000 after buying an additional 13,402 shares during the period. Thompson Davis & CO. Inc. acquired a new stake in iCAD in the 4th quarter valued at $31,000. Finally, Geode Capital Management LLC boosted its holdings in shares of iCAD by 6.6% in the 4th quarter. Geode Capital Management LLC now owns 276,493 shares of the technology company's stock valued at $506,000 after buying an additional 17,059 shares during the last quarter. 24.61% of the stock is currently owned by hedge funds and other institutional investors.

iCAD Trading Up 3.2 %

Shares of iCAD stock traded up $0.11 during trading on Wednesday, hitting $3.60. The stock had a trading volume of 546,370 shares, compared to its average volume of 387,239. iCAD, Inc. has a 12 month low of $1.18 and a 12 month high of $3.78. The firm has a market cap of $98.81 million, a price-to-earnings ratio of -27.69 and a beta of 1.35. The business's 50-day moving average is $2.47 and its 200 day moving average is $2.29.

iCAD (NASDAQ:ICAD - Get Free Report) last released its quarterly earnings results on Wednesday, March 19th. The technology company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.02. The firm had revenue of $5.41 million for the quarter, compared to analysts' expectations of $4.72 million. iCAD had a negative return on equity of 15.65% and a negative net margin of 17.81%.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Laidlaw reissued a "hold" rating on shares of iCAD in a report on Thursday, April 17th. StockNews.com began coverage on iCAD in a research note on Sunday. They issued a "sell" rating for the company. Craig Hallum lowered shares of iCAD from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, April 16th. Finally, BTIG Research downgraded shares of iCAD from a "buy" rating to a "neutral" rating in a research report on Wednesday, April 16th.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.